2009-05-11 ACHEMA 2009, 29. International Exhibition-Congress on Chemical Engineering, Environmental Protection and Biotechnology DECHEMA Frankfurt, Germany
Experts, Executives and Users in Dialogue
The congress programme, consisting of 925 lectures attended by some 27,000 visitors, is the second cornerstone of ACHEMA next to the exhibition itself. Numerous special and guest events, podium discussions, expert talks and plenary lectures provide a multi-faceted, highly topical and high level congress programme reflecting the great diversity of process engineering. Podium discussions with leading personalities from the fields of science, business and politics as well as many guest events, among others those organised by the International Association for Social Security (IVSS), the VDI-GVC Association for Process and Chemical Engineering and the GDCh Association of German Chemists, will round off the ACHEMA 2009 lecture programme.
2009-04-28 Advances in Synthetic Biology Conference Select Biosciences Ltd. London, England Synthetic biology is the design and construction of new biological parts, devices and systems (and the re-design of existing, natural biological systems) for useful purposes. Its interdisciplinary nature between science and engineering, as well as the many potential applications in the health, material and energy sectors, make this a particularly interesting conference.
The Chemistry of Synthetic Biology,
Protein, Metabolic & Therapeutic Engineering,
Bioinformatics and Software modeling in Synthetic Biology,
Cell & Tissue Engineering,
Rational and Systemic Design of Novel Biological Systems.
2009-04-16 2009 BioFine Europe sp2 Freiburg, Germany Synthetic biology has overcome almost all the limitations of previous genetic engineering methodology by developing de-novo syntheses of genes. With the design of artificial genetic elements, it has started to move away from natural genes and to establish artificial functionality. This is leading to the programming of cells in order to create desired genetic features and towards ensuring safety and security in handling this technology as an industrial process.
Analysing the differences between the American and the European way of how synthetic biology has been implemented into existing life science research and industry clearly shows that originally different driving forces are now producing similar results. In the USA, synthetic biology was developed through the research activities of a number of high-level public academic institutions and some private initiatives.
In contrast, Europe first accessed synthetic biology through the activities of pioneering technology companies in the field of de-novo gene synthesis, which created visibility in the marketplace and provided new technologies for improving the genetic engineering experiments of their customers. Now, as a consequence of international academic awareness of synthetic biology, the EU has catalysed the formation of the synthetic biology community in Europe within its NEST (new and emerging science and technology) programme. There are now activities being implemented in the UK, France, Germany, Italy, Spain, the Netherlands and other European countries.
Future exploitation of synthetic biology will be in many application fields, such as drug development and production, gene and cell therapies, medical supply, and increasingly in industrial biotechnology for improving processes, saving energy, improving product quality, and providing new opportunities not previously recognised.
The new trends are mostly guided by security and safety requirements and, as in the USA, operate in accordance with UN and WHO/WTO guidelines for sustainable growth and improvement of the quality of life on a worldwide basis.
In order to reflect the growing importance of this new area of technology we are delighted to announce the first Applied Industrial Synthetic Biology in Europe conference. This 2 day dual-track conference will feature more than 40 world-renowned experts from the field of synthetic biology and its end-use applications.
2009-01-22 2nd Annual Recombinant Antibodies Conference 2009 - Examining the latest developments in the field of antibody engineering Visiongain Ltd London Key Themes discussed at this unique conference:
• Identify novel antigens and target validation
• Implement breakthrough research in antibody engineering for enhanced effector functions
• Conduct a competitive analysis on develop and optimising effector functions
• Learn best practice strategies for agonistic and antagonistic antibodies
• Discover the do’s and don’ts of immunotoxins
• Acquire information on expanding indications for antibody therapy through improved drug delivery
• Discover recent antibody developments in various therapeutic
• Conduct a competitive analysis on results of long term therapy using antibodies
• Get tips on monitoring results from the clinic through biomarkers for antibody efficiency
• Get up-to-date knowledge on modern strategies to antibodies in targeting and imaging
Recombinant antibodies have distinct advantages compared with conventional antibodies, such as rapid growth, ease of manipulation and they can be produced in large quantities at a low cost. This makes them the ideal choice for expression of non-glycosylated peptides and proteins. Innovative product classes such as antibody fragments or alternative binding molecules will further expand the use of microbial systems, whilst novel engineered production hosts and integrated technology platforms hold enormous potential for future applications.
By attending visiongain's 2nd Annual Recombinant Antibodies Conference you will gain a comprehensive outlook for the protein therapeutics market from product development to strategic issues and market trends.
2008-12-12 1st Annual Meeting of the Program of Medical Genome Research NGFN Helmholtz Zentrum München 1st Annual Meeting of the Program of Medical Genome Research - which will be the "Kick-off Meeting for NGFN-Plus and NGFN-Transfer" as well as the 7th annual meeting of the German National Genome Research Network (NGFN)
at Helmholtz Zentrum München on December 12 and 13, 2008.
Main topics will be:
* Genomics of Common Disease
* Genome Regulation
* Animal, Cellular & Tissue Models
* Systems Biology
* Genomic / Environmental
* Transfer from Genomics to
Additional workshops on Next-Generation Sequencing and Genome-Wide Association Studies will be held on Thursday, December 11, 2008.
2008-12-01 Frontiers in Synthetic Biology 2008 GeneExpression Systems, Inc. Boston, Massachsetts, USA Engineering Genes, Genomes & Cells for Drug Discovery.
A Unique Theme to Combine Chemical Biology & Engineering Life.
The Most Innovative Global Theme Event in the Chemical Biology Field!
The most-up-to-date developments will be addressed in the following topics:
Genomes and Organelle Synthesis,
Constructive & Digital Biology,
Synthetic Biology & Ethics
2008-10-10 Synthetic Biology 4.0 BioBricks Foundation Hong Kong, China The organization of the event is being led by the BioBricks Foundation in partnership with the Hong Kong University of Science and Technology (HKUST), the University of Hong Kong (HKU), and the Chinese University of Hong Kong (CUHK).
SB4.0 will be a significant meeting, building on the past successes of SB1.0 (MIT), 2.0 (UC Berkeley), and 3.0 (ETH Zurich).
2008-06-26 NewSynBio Epigenesis, workshop on Design Strategies for Synthetic Biology Epigenomics Project, Genopole® ÉVRY cedex / France The Epigenomics Project is an institute of complex studies dedicated to the new biology. Following two years of scientific grounding, it has been founded in December 2002 by Genopole® which provides its main financial support, and it has had a physical location since January 2004.